Aurinia Pharmaceuticals - 1792 Exchange

Rating Overview

Aurinia Pharmaceuticals is Lower Risk.

Aurinia Pharmaceuticals is Lower Risk. The company does not yield to political activism in shaping corporate governance, preventing initiatives that potentially alienate consumers, divide employees, and harm shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Overall, Aurinia Pharmaceuticals does not embrace corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach protects free exercise, free speech, and free enterprise.

Rating Criteria

Corporate Weaponization Risk Levels
Criteria	Risk Level
Cancellations	Lower Risk
Discriminatory Philanthropy	Lower Risk
Employment Protection	High Risk

Corporate Weaponization ⓘ

Corporate Governance and Public Policy Risk Levels
Criteria	Risk Level
Advocacy Bias	High Risk
Funding	Lower Risk
Political Actions	No Data

Corporate Governance and Public Policy ⓘ

Rating Criteria Detail

Criteria Risk Level Rationale

Corporate Weaponization

Criteria:

Has canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.

Risk Level:

Lower

Rationale:

Aurinia Pharmaceuticals has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs (1).

Criteria:

Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.

Risk Level:

Lower

Rationale:

Aurinia Pharmaceuticals does not appear to discriminate against charitable organizations based on views or beliefs (1).

Criteria:

Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.

Risk Level:

High

Rationale:

Aurinia Pharmaceuticals requires its employees to take “an annual training related to diversity inclusive of age, race, color, gender, sexual preference, nationality, or physical ability” (1). The company appears to prioritize diversity over merit in its leadership composition. From its 2023 ESG Report: “We have adopted a written Diversity Policy, which focuses on the identification and nomination of directors and executive officers, and requires that the Board of Directors consider diversity on the Board from several aspects, including but not limited to gender, age, ethnicity and cultural diversity” (2). The company does not provide viewpoint protections for its employees (3).

Corporate Governance and Public Policy

Criteria:

Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.

Risk Level:

High

Rationale:

Aurinia Pharmaceuticals supports DEI within its business practices. From its 2023 ESG Report: “We are committed to cultivating a highly engaged workforce by continually incorporating authentic diversity, equity, equality, and inclusion efforts into our behaviors and culture to create an organization rich with ideas, perspectives, and experiences” (1). The company supports ESG within its business practices. From its 2023 ESG Report: “Though our employees have not formally been delegated responsibility for management of sustainability-related topics or impact management in our corporate governance, each employee has a role in advancing ESG within Aurinia” (2)(3).

Criteria:

Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.

Risk Level:

Lower

Rationale:

Aurinia Pharmaceuticals has not used corporate funds to advance ideological causes, organizations, or policies (1).

Criteria:

Uses corporate political actions and/or financial contributions for ideological, non-business purposes.

Risk Level:

N/A

Rationale:

Aurinia Pharmaceuticals does not operate a PAC or report on its lobbying at this time (1)(2)(3).